TILInstil Bio, Inc.

Nasdaq instilbio.com


$ 12.13 $ -0.30 (-2.54 %)    

Wednesday, 15-May-2024 15:55:49 EDT
QQQ $ 451.63 $ -0.22 (-0.05 %)
DIA $ 399.76 $ 0.74 (0.19 %)
SPY $ 529.24 $ 0.76 (0.14 %)
TLT $ 91.40 $ -0.62 (-0.67 %)
GLD $ 223.63 $ 3.63 (1.65 %)
$ 11.5
$ 12.13
$ 0.00 x 0
$ 0.00 x 0
$ 12.13 - $ 12.13
$ 6.07 - $ 13.04
963
na
74.8M
$ 4.94
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-10-2024 03-31-2024 10-Q
2 03-21-2024 12-31-2023 10-K
3 11-13-2023 09-30-2023 10-Q
4 08-14-2023 06-30-2023 10-Q
5 05-11-2023 03-31-2023 10-Q
6 03-31-2023 12-31-2022 10-K
7 11-14-2022 09-30-2022 10-Q
8 08-12-2022 06-30-2022 10-Q
9 05-16-2022 03-31-2022 10-Q
10 03-07-2022 12-31-2021 10-K
11 11-15-2021 09-30-2021 10-Q
12 08-12-2021 06-30-2021 10-Q
13 05-13-2021 03-31-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-instil-bio-maintains-18-price-target

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Instil Bio (NASDAQ:TIL) with a Buy and maintains $18 price target.

 baird-maintains-outperform-on-instil-bio-lowers-price-target-to-32

Baird analyst Jack Allen maintains Instil Bio (NASDAQ:TIL) with a Outperform and lowers the price target from $54 to $32.

 instil-bio-q1-2024-gaap-eps-239-misses-223-estimate

Instil Bio (NASDAQ:TIL) reported quarterly losses of $(2.39) per share which missed the analyst consensus estimate of $(2.23) b...

 jefferies-downgrades-instil-bio-to-hold-raises-price-target-to-11

Jefferies analyst Kelly Shi downgrades Instil Bio (NASDAQ:TIL) from Buy to Hold and raises the price target from $5 to $11.

 hc-wainwright--co-reiterates-buy-on-instil-bio-maintains-18-price-target

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Instil Bio (NASDAQ:TIL) with a Buy and maintains $18 price target.

 instil-bio-q4-adj-eps-126-beats-285-estimate

Instil Bio (NASDAQ:TIL) reported quarterly Adj losses of $(1.26) per share which beat the analyst consensus estimate of $(2.85)...

 hc-wainwright--co-maintains-buy-on-instil-bio-adjusts-price-target-to-18

HC Wainwright & Co. analyst Mitchell Kapoor maintains Instil Bio (NASDAQ:TIL) with a Buy, adjusts target to $18 from $2.

 baird-reiterates-outperform-on-instil-bio-maintains-54-price-target

Baird analyst Jack Allen reiterates Instil Bio (NASDAQ:TIL) with a Outperform and maintains $54 price target.

 baird-maintains-outperform-on-instil-bio-lowers-price-target-to-54

Baird analyst Jack Allen maintains Instil Bio (NASDAQ:TIL) with a Outperform and lowers the price target from $100 to $54.

 instil-bio-says-as-result-of-workforce-reduction-co-no-longer-expects-to-report-clinical-data-from-itil-306-202-clinical-trial-in-2024-in-connection-with-restructuring-plan-estimates-that-it-will-incur-aggregate-restructuring-costs-of-up-to-61m

-SEC Filing

 instil-bio-partners-with-cell-therapy-leader-for-itil-306-program-eyeing-breakthrough-in-lung-cancer-treatment

Instil Bio, Inc. ("Instil" or the "Company") (NASDAQ:TIL), a clinical-stage biopharmaceutical company focused o...

 hc-wainwright--co-reiterates-buy-on-instil-bio-maintains-2-price-target

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Instil Bio (NASDAQ:TIL) with a Buy and maintains $2 price target.

 update-instil-bio-q3-adj-eps-016-misses-010-estimate

Instil Bio (NASDAQ:TIL) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.10) b...

 instil-bio-q3-adj-eps-016-misses-010-estimate

Instil Bio (NASDAQ: TIL) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.10) ...

 hc-wainwright--co-reiterates-buy-on-instil-bio-maintains-2-price-target

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Instil Bio (NASDAQ:TIL) with a Buy and maintains $2 price target.

 update-instil-bio-q2-adj-011-beats-016-estimate

Instil Bio (NASDAQ:TIL) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.16) by ...

 instil-bio-q2-adj-011-beats-016-estimate-cash-balance-2029m-confirms-prior-guidance-of-cash-runway-beyond-2026

Instil Bio (NASDAQ: TIL) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.16) by...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION